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Predominance of the ﬁmH30
Subclone AmongMultidrug-
Resistant Escherichia coli
Strains Belonging to
Sequence Type 131 in Italy
TO THE EDITOR—We read with interest
the article by Johnson et al, which demon-
strates that, in extraintestinal pathogenic
Escherichia coli (ExPEC), ﬂuoroquinolone
(FQ) resistance is currently associated
with the rapid expansion of a single dom-
inant multidrug-resistant (MDR) strain
that emerged within sequence type (ST)
131 [1]. Although the strong predomi-
nance of the ST131 clone has been well
described in the literature since 2008 [2–
5], the peculiarity of Johnson et al’s study
was to analyze historical and recent
ST131 isolates at the sub-ST level, reveal-
ing that a speciﬁc ﬁmH-based subclone
(H30) is currently responsible for most
FQ-resistant ExPEC infections, at least in
the United States. This H30 subclone was
demonstrated to possess a unique and
conserved gyrA/parC allele combination
conferring FQ resistance, and the authors
rightly commented on these data in
support of its strict clonality. We are par-
ticularly interested in this issue, since
ST131 is also currently predominant
among MDR ExPEC in Italy and because
some ST131 strains we previously ana-
lyzed were found to carry the same pattern
of gyrA/parC substitutions described by
Johnson et al [1, 6]. No information is
available on the ﬁmH-based subclones
circulating in European countries.
In this study, 172 ExPEC strains isolat-
ed from cases of urinary tract infections
and sepsis in Italy during April 2012–
December 2012 were analyzed. Staff a the
3 enrolled hospitals were asked to collect
all consecutive MDR E. coli strains and 1
ciproﬂoxacin-susceptible non-MDR E. coli
strain for every 3 MDR strains collected.
“MDR” was deﬁned as resistance to at
least 3 antimicrobial agents of different
classes (ampicillin, third-generation ceph-
alosporins, ciproﬂoxacin, gentamicin, and
trimethoprim/sulfamethoxazole). Of 172
strains, 119 were MDR strains that were
resistant to ciproﬂoxacin; 9 were MDR
strains that were susceptible to ciproﬂox-
acin; and 44 were non-MDR strains that
were susceptible to ciproﬂoxacin. Anti-
microbial susceptibility testing, phyloge-
netic typing, polymerase chain reaction
screening for ST131 followed by conﬁrma-
tion (by mdh and gyrB gene sequencing),
characterization of the extended-spectrum
β-lactamase (ESBL) and/or AmpC genes,
and ﬁmH-based subtyping of the ST131
strains were performed as previously de-
scribed [1, 7–9]. To investigate which ﬁmH
allele circulated in Italy before 2012, an ad-
ditional 91 E. coli ST131 strains previously
identiﬁed were also subtyped [7, 10]. Of
these 91 strains, 28 (24 ciproﬂoxacin-
resistant strains and 4 ciproﬂoxacin-
susceptible strains) were isolated in 2006,
and 63 (58 ciproﬂoxacin-resistant strains
and 4 ciproﬂoxacin-susceptible strains)
were isolated in 2009.
By phylogenetic typing, overall, the
majority of strains isolated in 2012 (110/
172 [64%]) fell into phylogenetic group
B2, followed by groups D (30/172 [17.4%]),
Table 1. Distribution of Extended-Spectrum β-Lactamase (ESBL)/AmpC types and ﬁmH
Alleles Among Sequence Type 131 Escherichia coli Strains Stratiﬁed by Ciproﬂoxacin
(CIP) Susceptibility and Multidrug Resistance (MDR) Status
MDR Strains, No. (%)
Non-MDR Strains, No. (%)
CIP Resistant (n = 73) CIP Susceptible (n = 4) CIP Susceptible (n = 6)
ESBL type
CTX-M-15 64 (87.7) 3 (75.0) . . .
CTX-M-1 . . . 1 (25.0) . . .
CTX-M-55 1 (1.4) . . . . . .
CTX-M-14 1 (1.4) . . . 1 (16.7)
AmpC type
CMY-2 . . . . . . 1 (16.7)
fimH allele
H30 73 (100) 3 (75.0) 5 (83.3)
H22 . . . 1 (25.0) 1 (16.7)
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A (17/172 [9.9%]), and B1 (13/172 [7.6%]);
2 strains were nontypeable. Most phy-
logroup B2 strains (83/110 [75.5%]) were
ST131. ST131 accounted for 61.3% (73/
119), 44.4% (4/9), and 13.6% (6/44) of
all MDR ciproﬂoxacin-resistant, MDR
ciproﬂoxacin-susceptible, and non-MDR
ciproﬂoxacin-susceptible strains, respec-
tively. Of the 83 ST131 strains, 72 (86.7%)
showed an ESBL phenotype. Most ESBL-
positive strains (71/72 [98.6%]) were
CTX-M positive: 67 strains contained
blaCTX-M-15, 1 containedblaCTX-M-1, 1 con-
tained bla
CTX-M-55
, and 2 contained blaCTX-
M-14 (Table 1). One strain carried
blaCMY2. When the 83 ST131 strains were
subtyped by ﬁmH sequencing, all but 2
were found to belong to the H30 subclone,
including 3 MDR ciproﬂoxacin-susceptible
strains and 5 non-MDR ciproﬂoxacin-
susceptible strains (Table 1). Both remain-
ing strains were H22 (one was MDR but
ciproﬂoxacin-susceptible strain, and the
other was a ciproﬂoxacin-susceptible non-
MDR strain; Table 1). Finally, the ﬁmH
subtyping of the 91 ST131 strains collected
in previous periods showed that the H30
subclone has predominated since at least
2006. In fact, 26 of 28 strains and 62 of 63
strains isolated in 2006 and 2009, respec-
tively, belonged to H30. The remaining 3
strains (all ciproﬂoxacin-susceptible non-
MDR strains) were H22.
Our data conﬁrmed that most FQ-
resistant MDR strains carrying CTX-
M15 ESBL are also currently associated
with the dominant H30 ST131 subclone
in Italy, indicating a worldwide dissemi-
nation of this subclone. According to the
study by Johnson et al, H30 expanded
abruptly after 2000 together with the
emergence of FQ resistance, whereas H22
predominated before then and was asso-
ciated with FQ susceptibility in both his-
torical and current isolates [1]. In our
study, the H22 subclone was rare even
among FQ-susceptible strains that mostly
belonged to H30, although the few H22
strains we found were all FQ susceptible.
It is possible that the epidemiology of the
ST131 subclones slightly differed in Italy
and that H30 was present before acquiring
FQ resistance. Unfortunately, we were not
able to analyze ExPEC isolates collected
before 2006. Therefore we cannot investi-
gate the emergence of the different ST131
subclones according to FQ susceptibility
status.
In conclusion, most MDR ExPEC in-
fections are currently due to the H30
ST131 subclone in Italy. We emphasize
the importance of performing investiga-
tions on the clonal structure of the “suc-
cessful” ST131 clone in different countries
and settings.
Notes
Acknowledgments. We thank Tonino Soﬁa,
for editorial assistance; and Alessandra Carattoli
(Istituto Superiore di Sanità), for helpful discus-
sion and comments.
Financial support. This work was supported
by the Ministry of Health–Centro Controllo Ma-
lattie (project title, “Surveillance on Antibiotic
Resistance in the Community and in Foodborne
and Zoonotic Diseases”; grant 3M24).
Potential conﬂicts of interest. All authors:
No reported conﬂicts.
All authors have submitted the ICMJE Form
for Disclosure of Potential Conﬂicts of Interest.
Conﬂicts that the editors consider relevant to the
content of the manuscript have been disclosed.
Maria Giufre,1,a Marisa Accogli,1,a
Claudio Farina,2 Anna Giammanco,3
Patrizia Pecile,4 and Marina Cerquetti1
1Department of Infectious, Parasitic and Immune-
mediated Diseases, Istituto Superiore di Sanità, Rome;
2Microbiology and Virology Institute, Azienda
Ospedaliera Papa Giovanni XXIII, Bergamo;
3Department of Sciences for Health Promotion and
Mother and Child Care G. D’Alessandro, University of
Palermo, Palermo; and 4Microbiology Laboratory,
Azienda Ospedaliero–Universitaria Careggi, Florence,
Italy
References
1. Johnson JR, Tchesnokova V, Johnston B,
et al. Abrupt emergence of a single dominant
multidrug-resistant strain of Escherichia coli.
J Infect Dis 2013; 207:919–28.
2. Nicolas-Chanoine MH, Blanco J, Leﬂon-
Guibout V, et al. Intercontinental emergence
of Escherichia coli clone O25:H4-ST131 pro-
ducing CTX-M-15. J Antimicrob Chemother
2008; 61:273–81.
3. Lau SH, Kaufmann ME, Livermore DM,
et al. UK epidemic Escherichia coli strains
A–E, with CTX-M-15 b-lactamase, all belong
to the international O25:H4-ST131 clone.
J Antimicrob Chemother 2008; 62:1241–4.
4. Cagnacci S, Gualco L, Debbia E, et al. Euro-
pean emergence of ciproﬂoxacin-resistant
Escherichia coli clonal groups O25: H4-ST
131 and O15:K52:H1 causing community-
acquired uncomplicated cystitis. J Clin Mi-
crobiol 2008; 46:2605–12.
5. Johnson JR, Johnston B, Clabots C, et al. Es-
cherichia coli Sequence Type ST131 as the
Major Cause of Serious Multidrug-Resistant
E. coli Infections in the United States. Clin
Infect Dis 2010; 51:286–94.
6. Cerquetti M, Giufrè M, García-Fernández A,
et al. Ciproﬂoxacin-resistant, CTX-M-15-
producing Escherichia coli ST131 clone in
extraintestinal infections in Italy. Clin Micro-
biol Infect 2010; 16:1555–8.
7. Giufrè M, Graziani C, Accogli M, et al. Es-
cherichia coli of human and avian origin:
detection of clonal groups associated with
ﬂuoroquinolone and multidrug resistance in
Italy. J Antimicrob Chemother 2012; 67:
860–7.
8. Clermont O, Christenson JK, Denamur E,
Gordon DM. The Clermont Escherichia coli
phylo-typing method revisited: improvement
of speciﬁcity and detection of new phylo-
groups. Environ Microbiol Rep 2013; 5:
58–65.
9. Dierikx C, van Essen-Zandbergen A, Veldman
K, et al. Increased detection of extended spec-
trum beta-lactamase producing Salmonella
enterica and Escherichia coli isolates from
poultry. Vet Microbiol 2010; 145:273–8.
10. Graziani C, Luzzi I, Corro M, et al. Phyloge-
netic background and virulence genotype of
ciproﬂoxacin-susceptible and ciproﬂoxacin-
resistant Escherichia coli strains of human
and avian origin. J Infect Dis 2009; 199:
1209–17.
Received 31 July 2013; accepted 17 September 2013.
aM. G. and M. A. contributed equally to this work.
Correspondence: Dr. Marina Cerquetti, Department of In-
fectious, Parasitic and Immune-mediated Diseases, Istituto
Superiore di Sanità, Viale Regina Elena, 299, 00161 Rome,
Italy (marina.cerquetti@iss.it).
The Journal of Infectious Diseases 2014;209:629–30
© The Author 2013. Published by Oxford University Press
on behalf of the Infectious Diseases Society of America.
All rights reserved. For Permissions, please e-mail: journals.
permissions@oup.com.
DOI: 10.1093/infdis/jit583
630 • JID 2014:209 (15 February) • CORRESPONDENCE
 by guest on M
arch 25, 2014
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
